watatwit
$ATOS long post, IMO of course. After 6+ years of being long, not selling in 2021 and watching my investment being diluted due to malfeasance, I have taken a $15K loss and moved on.
I was confidently bet this small amount on Endoxifen and its potential to treat breast cancer. My confidence in this drug is still there. My mistake was failing to be diligent when it comes to the executive leadership of Atossa.
I do not believe Steven Quay has even the most remote of intentions to bring Endoxifen to market. I believe he is far more interested in funding his lifestyle as a scientist and padding his retirement off the backs of retail investors.
I believe the revolving door of executives, legal counsel, PR reps, etc. is due to those people coming to the same conclusion.
10
